Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc (CNTA) Stock Competitors & Peer Comparison
See (CNTA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CNTA | $39.60 | +0.05% | 6.1B | -22.25 | -$1.78 | N/A |
| VRTX | $450.41 | -0.58% | 114.3B | 26.75 | $16.84 | N/A |
| REGN | $712.87 | -0.97% | 73.4B | 17.49 | $40.75 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $822.13 | +2.42% | 50.9B | 36.57 | $22.48 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $293.45 | +0.68% | 39.2B | 73.55 | $3.99 | N/A |
| RVMD | $149.47 | -0.31% | 31.7B | -20.40 | -$7.32 | N/A |
| INSM | $115.62 | -2.01% | 25.1B | -20.07 | -$5.76 | N/A |
| UTHR | $575.79 | -0.65% | 24.4B | 21.29 | $27.05 | N/A |
Stock Comparison
CNTA vs VRTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, VRTX has a market cap of 114.3B. Regarding current trading prices, CNTA is priced at $39.60, while VRTX trades at $450.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas VRTX's P/E ratio is 26.75. In terms of profitability, CNTA's ROE is -0.60%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CNTA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check VRTX's competition here
CNTA vs REGN Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, REGN has a market cap of 73.4B. Regarding current trading prices, CNTA is priced at $39.60, while REGN trades at $712.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas REGN's P/E ratio is 17.49. In terms of profitability, CNTA's ROE is -0.60%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CNTA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check REGN's competition here
CNTA vs VRNA Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CNTA is priced at $39.60, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CNTA's ROE is -0.60%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, CNTA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check VRNA's competition here
CNTA vs ARGX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ARGX has a market cap of 50.9B. Regarding current trading prices, CNTA is priced at $39.60, while ARGX trades at $822.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ARGX's P/E ratio is 36.57. In terms of profitability, CNTA's ROE is -0.60%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, CNTA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ARGX's competition here
CNTA vs SGEN Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CNTA is priced at $39.60, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CNTA's ROE is -0.60%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CNTA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check SGEN's competition here
CNTA vs ALNY Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ALNY has a market cap of 39.2B. Regarding current trading prices, CNTA is priced at $39.60, while ALNY trades at $293.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ALNY's P/E ratio is 73.55. In terms of profitability, CNTA's ROE is -0.60%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, CNTA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ALNY's competition here
CNTA vs RVMD Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, RVMD has a market cap of 31.7B. Regarding current trading prices, CNTA is priced at $39.60, while RVMD trades at $149.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas RVMD's P/E ratio is -20.40. In terms of profitability, CNTA's ROE is -0.60%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CNTA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check RVMD's competition here
CNTA vs INSM Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, CNTA is priced at $39.60, while INSM trades at $115.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas INSM's P/E ratio is -20.07. In terms of profitability, CNTA's ROE is -0.60%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CNTA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check INSM's competition here
CNTA vs UTHR Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, UTHR has a market cap of 24.4B. Regarding current trading prices, CNTA is priced at $39.60, while UTHR trades at $575.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas UTHR's P/E ratio is 21.29. In terms of profitability, CNTA's ROE is -0.60%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CNTA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check UTHR's competition here
CNTA vs BNTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, CNTA is priced at $39.60, while BNTX trades at $91.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas BNTX's P/E ratio is -15.41. In terms of profitability, CNTA's ROE is -0.60%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CNTA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BNTX's competition here
CNTA vs RPRX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, RPRX has a market cap of 23B. Regarding current trading prices, CNTA is priced at $39.60, while RPRX trades at $53.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas RPRX's P/E ratio is 28.11. In terms of profitability, CNTA's ROE is -0.60%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, CNTA is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check RPRX's competition here
CNTA vs ROIV Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ROIV has a market cap of 21.1B. Regarding current trading prices, CNTA is priced at $39.60, while ROIV trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ROIV's P/E ratio is -25.21. In terms of profitability, CNTA's ROE is -0.60%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, CNTA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ROIV's competition here
CNTA vs BGNE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CNTA is priced at $39.60, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CNTA's ROE is -0.60%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CNTA is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BGNE's competition here
CNTA vs MRNA Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, MRNA has a market cap of 19.9B. Regarding current trading prices, CNTA is priced at $39.60, while MRNA trades at $50.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas MRNA's P/E ratio is -6.15. In terms of profitability, CNTA's ROE is -0.60%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, CNTA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MRNA's competition here
CNTA vs INCY Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, INCY has a market cap of 19.5B. Regarding current trading prices, CNTA is priced at $39.60, while INCY trades at $97.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas INCY's P/E ratio is 13.79. In terms of profitability, CNTA's ROE is -0.60%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CNTA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check INCY's competition here
CNTA vs DNA-WT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CNTA is priced at $39.60, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CNTA's ROE is -0.60%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CNTA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check DNA-WT's competition here
CNTA vs GMAB Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, GMAB has a market cap of 16.5B. Regarding current trading prices, CNTA is priced at $39.60, while GMAB trades at $26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas GMAB's P/E ratio is 20.53. In terms of profitability, CNTA's ROE is -0.60%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, CNTA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check GMAB's competition here
CNTA vs ASND Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ASND has a market cap of 15.2B. Regarding current trading prices, CNTA is priced at $39.60, while ASND trades at $245.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ASND's P/E ratio is 27.52. In terms of profitability, CNTA's ROE is -0.60%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CNTA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ASND's competition here
CNTA vs JAZZ Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, CNTA is priced at $39.60, while JAZZ trades at $231.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas JAZZ's P/E ratio is 2100.45. In terms of profitability, CNTA's ROE is -0.60%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CNTA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check JAZZ's competition here
CNTA vs SMMT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, SMMT has a market cap of 14.1B. Regarding current trading prices, CNTA is priced at $39.60, while SMMT trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas SMMT's P/E ratio is -11.41. In terms of profitability, CNTA's ROE is -0.60%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, CNTA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check SMMT's competition here
CNTA vs BBIO Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, BBIO has a market cap of 13.6B. Regarding current trading prices, CNTA is priced at $39.60, while BBIO trades at $69.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas BBIO's P/E ratio is -18.63. In terms of profitability, CNTA's ROE is -0.60%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CNTA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BBIO's competition here
CNTA vs EXEL Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, EXEL has a market cap of 12.8B. Regarding current trading prices, CNTA is priced at $39.60, while EXEL trades at $51.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas EXEL's P/E ratio is 16.92. In terms of profitability, CNTA's ROE is -0.60%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CNTA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check EXEL's competition here
CNTA vs KRTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CNTA is priced at $39.60, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CNTA's ROE is -0.60%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CNTA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check KRTX's competition here
CNTA vs IONS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, CNTA is priced at $39.60, while IONS trades at $75.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas IONS's P/E ratio is -37.65. In terms of profitability, CNTA's ROE is -0.60%, compared to IONS's ROE of -0.59%. Regarding short-term risk, CNTA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check IONS's competition here
CNTA vs MDGL Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, CNTA is priced at $39.60, while MDGL trades at $539.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas MDGL's P/E ratio is -40.08. In terms of profitability, CNTA's ROE is -0.60%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, CNTA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MDGL's competition here
CNTA vs AXSM Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, CNTA is priced at $39.60, while AXSM trades at $232.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas AXSM's P/E ratio is -62.44. In terms of profitability, CNTA's ROE is -0.60%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CNTA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check AXSM's competition here
CNTA vs RNAM Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CNTA is priced at $39.60, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CNTA's ROE is -0.60%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CNTA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RNAM's competition here
CNTA vs ARWR Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ARWR has a market cap of 11.2B. Regarding current trading prices, CNTA is priced at $39.60, while ARWR trades at $79.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ARWR's P/E ratio is -35.11. In terms of profitability, CNTA's ROE is -0.60%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CNTA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ARWR's competition here
CNTA vs BMRN Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, BMRN has a market cap of 10.3B. Regarding current trading prices, CNTA is priced at $39.60, while BMRN trades at $53.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas BMRN's P/E ratio is 38.30. In terms of profitability, CNTA's ROE is -0.60%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CNTA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BMRN's competition here
CNTA vs CYTK Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, CNTA is priced at $39.60, while CYTK trades at $78.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CYTK's P/E ratio is -11.48. In terms of profitability, CNTA's ROE is -0.60%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, CNTA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CYTK's competition here
CNTA vs RXDX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CNTA is priced at $39.60, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CNTA's ROE is -0.60%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CNTA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RXDX's competition here
CNTA vs KRYS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, KRYS has a market cap of 9.3B. Regarding current trading prices, CNTA is priced at $39.60, while KRYS trades at $316.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas KRYS's P/E ratio is 42.34. In terms of profitability, CNTA's ROE is -0.60%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CNTA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check KRYS's competition here
CNTA vs IMGN Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CNTA is priced at $39.60, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CNTA's ROE is -0.60%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CNTA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check IMGN's competition here
CNTA vs IBRX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, CNTA is priced at $39.60, while IBRX trades at $8.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas IBRX's P/E ratio is -9.59. In terms of profitability, CNTA's ROE is -0.60%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CNTA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check IBRX's competition here
CNTA vs BPMC Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CNTA is priced at $39.60, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CNTA's ROE is -0.60%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, CNTA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check BPMC's competition here
CNTA vs HALO Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, CNTA is priced at $39.60, while HALO trades at $69.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas HALO's P/E ratio is 24.28. In terms of profitability, CNTA's ROE is -0.60%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CNTA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check HALO's competition here
CNTA vs CERE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CNTA is priced at $39.60, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CERE's P/E ratio is -16.47. In terms of profitability, CNTA's ROE is -0.60%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CNTA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CERE's competition here
CNTA vs ABVX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ABVX has a market cap of 7.9B. Regarding current trading prices, CNTA is priced at $39.60, while ABVX trades at $121.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ABVX's P/E ratio is -21.15. In terms of profitability, CNTA's ROE is -0.60%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, CNTA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ABVX's competition here
CNTA vs PCVX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, PCVX has a market cap of 7.7B. Regarding current trading prices, CNTA is priced at $39.60, while PCVX trades at $53.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas PCVX's P/E ratio is -7.74. In terms of profitability, CNTA's ROE is -0.60%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CNTA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check PCVX's competition here
CNTA vs NUVL Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, CNTA is priced at $39.60, while NUVL trades at $104.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas NUVL's P/E ratio is -17.23. In terms of profitability, CNTA's ROE is -0.60%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CNTA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check NUVL's competition here
CNTA vs MTSR Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CNTA is priced at $39.60, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CNTA's ROE is -0.60%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CNTA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MTSR's competition here
CNTA vs PRAX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, CNTA is priced at $39.60, while PRAX trades at $345.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas PRAX's P/E ratio is -25.82. In terms of profitability, CNTA's ROE is -0.60%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CNTA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check PRAX's competition here
CNTA vs TECH Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, TECH has a market cap of 7B. Regarding current trading prices, CNTA is priced at $39.60, while TECH trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas TECH's P/E ratio is 63.91. In terms of profitability, CNTA's ROE is -0.60%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CNTA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check TECH's competition here
CNTA vs KYMR Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, CNTA is priced at $39.60, while KYMR trades at $84.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas KYMR's P/E ratio is -23.60. In terms of profitability, CNTA's ROE is -0.60%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CNTA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check KYMR's competition here
CNTA vs MRUS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CNTA is priced at $39.60, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CNTA's ROE is -0.60%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CNTA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MRUS's competition here
CNTA vs PTGX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, PTGX has a market cap of 6.8B. Regarding current trading prices, CNTA is priced at $39.60, while PTGX trades at $105.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas PTGX's P/E ratio is -58.31. In terms of profitability, CNTA's ROE is -0.60%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CNTA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check PTGX's competition here
CNTA vs ACLX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CNTA is priced at $39.60, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CNTA's ROE is -0.60%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CNTA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ACLX's competition here
CNTA vs RETA Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CNTA is priced at $39.60, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas RETA's P/E ratio is -66.29. In terms of profitability, CNTA's ROE is -0.60%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CNTA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RETA's competition here
CNTA vs CELC Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CELC has a market cap of 6.5B. Regarding current trading prices, CNTA is priced at $39.60, while CELC trades at $134.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CELC's P/E ratio is -35.55. In terms of profitability, CNTA's ROE is -0.60%, compared to CELC's ROE of -2.03%. Regarding short-term risk, CNTA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CELC's competition here
CNTA vs RYTM Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, CNTA is priced at $39.60, while RYTM trades at $93.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas RYTM's P/E ratio is -29.91. In terms of profitability, CNTA's ROE is -0.60%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CNTA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check RYTM's competition here
CNTA vs ALKS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ALKS has a market cap of 6.4B. Regarding current trading prices, CNTA is priced at $39.60, while ALKS trades at $38.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ALKS's P/E ratio is 42.62. In terms of profitability, CNTA's ROE is -0.60%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, CNTA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ALKS's competition here
CNTA vs CORT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CORT has a market cap of 6.3B. Regarding current trading prices, CNTA is priced at $39.60, while CORT trades at $58.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CORT's P/E ratio is 166.57. In terms of profitability, CNTA's ROE is -0.60%, compared to CORT's ROE of +0.08%. Regarding short-term risk, CNTA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CORT's competition here
CNTA vs TGTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, TGTX has a market cap of 6.2B. Regarding current trading prices, CNTA is priced at $39.60, while TGTX trades at $40.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas TGTX's P/E ratio is 14.26. In terms of profitability, CNTA's ROE is -0.60%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CNTA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check TGTX's competition here
CNTA vs SRRK Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, SRRK has a market cap of 6.1B. Regarding current trading prices, CNTA is priced at $39.60, while SRRK trades at $51.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas SRRK's P/E ratio is -14.86. In terms of profitability, CNTA's ROE is -0.60%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CNTA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check SRRK's competition here
CNTA vs CGON Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, CNTA is priced at $39.60, while CGON trades at $69.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CGON's P/E ratio is -29.72. In terms of profitability, CNTA's ROE is -0.60%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CNTA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CGON's competition here
CNTA vs PTCT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, PTCT has a market cap of 6B. Regarding current trading prices, CNTA is priced at $39.60, while PTCT trades at $72.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas PTCT's P/E ratio is -28.63. In terms of profitability, CNTA's ROE is -0.60%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, CNTA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check PTCT's competition here
CNTA vs BLTE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, CNTA is priced at $39.60, while BLTE trades at $149.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas BLTE's P/E ratio is -64.91. In terms of profitability, CNTA's ROE is -0.60%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, CNTA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BLTE's competition here
CNTA vs IMVT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, CNTA is priced at $39.60, while IMVT trades at $28.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas IMVT's P/E ratio is -10.85. In terms of profitability, CNTA's ROE is -0.60%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, CNTA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check IMVT's competition here
CNTA vs COGT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, CNTA is priced at $39.60, while COGT trades at $34.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas COGT's P/E ratio is -15.76. In terms of profitability, CNTA's ROE is -0.60%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CNTA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check COGT's competition here
CNTA vs CDTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CNTA is priced at $39.60, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CNTA's ROE is -0.60%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CNTA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CDTX's competition here
CNTA vs MIRM Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, CNTA is priced at $39.60, while MIRM trades at $111.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas MIRM's P/E ratio is -8.19. In terms of profitability, CNTA's ROE is -0.60%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CNTA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MIRM's competition here
CNTA vs ABCM Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CNTA is priced at $39.60, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CNTA's ROE is -0.60%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CNTA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ABCM's competition here
CNTA vs ISEE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CNTA is priced at $39.60, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CNTA's ROE is -0.60%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CNTA is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ISEE's competition here
CNTA vs LEGN Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, CNTA is priced at $39.60, while LEGN trades at $28.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas LEGN's P/E ratio is -20.72. In terms of profitability, CNTA's ROE is -0.60%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, CNTA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check LEGN's competition here
CNTA vs LQDA Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, LQDA has a market cap of 5.3B. Regarding current trading prices, CNTA is priced at $39.60, while LQDA trades at $59.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas LQDA's P/E ratio is 348.82. In terms of profitability, CNTA's ROE is -0.60%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, CNTA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check LQDA's competition here
CNTA vs APLS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CNTA is priced at $39.60, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas APLS's P/E ratio is 38.35. In terms of profitability, CNTA's ROE is -0.60%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CNTA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check APLS's competition here
CNTA vs APGE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, CNTA is priced at $39.60, while APGE trades at $83.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas APGE's P/E ratio is -19.38. In terms of profitability, CNTA's ROE is -0.60%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CNTA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check APGE's competition here
CNTA vs FBIOX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, CNTA is priced at $39.60, while FBIOX trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CNTA's ROE is -0.60%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, CNTA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check FBIOX's competition here
CNTA vs CRSP Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, CNTA is priced at $39.60, while CRSP trades at $50.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CRSP's P/E ratio is -8.18. In terms of profitability, CNTA's ROE is -0.60%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CNTA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CRSP's competition here
CNTA vs TERN Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CNTA is priced at $39.60, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas TERN's P/E ratio is -51.41. In terms of profitability, CNTA's ROE is -0.60%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CNTA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check TERN's competition here
CNTA vs SYRE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, SYRE has a market cap of 4.6B. Regarding current trading prices, CNTA is priced at $39.60, while SYRE trades at $75.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas SYRE's P/E ratio is -35.68. In terms of profitability, CNTA's ROE is -0.60%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CNTA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check SYRE's competition here
CNTA vs FOLD Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CNTA is priced at $39.60, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CNTA's ROE is -0.60%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CNTA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check FOLD's competition here
CNTA vs AKRO Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CNTA is priced at $39.60, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CNTA's ROE is -0.60%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CNTA is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check AKRO's competition here
CNTA vs ALPN Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CNTA is priced at $39.60, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CNTA's ROE is -0.60%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CNTA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ALPN's competition here
CNTA vs XENE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $39.60, while XENE trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas XENE's P/E ratio is -11.91. In terms of profitability, CNTA's ROE is -0.60%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CNTA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check XENE's competition here
CNTA vs KNSA Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, KNSA has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $39.60, while KNSA trades at $58.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas KNSA's P/E ratio is 64.33. In terms of profitability, CNTA's ROE is -0.60%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, CNTA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check KNSA's competition here
CNTA vs LGND Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $39.60, while LGND trades at $218.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas LGND's P/E ratio is 28.59. In terms of profitability, CNTA's ROE is -0.60%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CNTA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check LGND's competition here
CNTA vs MANE Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $39.60, while MANE trades at $106.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas MANE's P/E ratio is -44.40. In terms of profitability, CNTA's ROE is -0.60%, compared to MANE's ROE of -0.76%. Regarding short-term risk, CNTA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MANE's competition here
CNTA vs NAMS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, NAMS has a market cap of 4.3B. Regarding current trading prices, CNTA is priced at $39.60, while NAMS trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas NAMS's P/E ratio is -20.72. In terms of profitability, CNTA's ROE is -0.60%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, CNTA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check NAMS's competition here
CNTA vs CAI Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CAI has a market cap of 4.3B. Regarding current trading prices, CNTA is priced at $39.60, while CAI trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CAI's P/E ratio is -5.53. In terms of profitability, CNTA's ROE is -0.60%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CNTA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CAI's competition here
CNTA vs OPT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CNTA is priced at $39.60, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas OPT's P/E ratio is -1.52. In terms of profitability, CNTA's ROE is -0.60%, compared to OPT's ROE of +0.88%. Regarding short-term risk, CNTA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check OPT's competition here
CNTA vs MRTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CNTA is priced at $39.60, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CNTA's ROE is -0.60%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CNTA is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MRTX's competition here
CNTA vs TVTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, TVTX has a market cap of 4.1B. Regarding current trading prices, CNTA is priced at $39.60, while TVTX trades at $44.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas TVTX's P/E ratio is -88.20. In terms of profitability, CNTA's ROE is -0.60%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CNTA is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check TVTX's competition here
CNTA vs CRNX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CRNX has a market cap of 4B. Regarding current trading prices, CNTA is priced at $39.60, while CRNX trades at $38.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CRNX's P/E ratio is -7.45. In terms of profitability, CNTA's ROE is -0.60%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CNTA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CRNX's competition here
CNTA vs CPRX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, CNTA is priced at $39.60, while CPRX trades at $31.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CPRX's P/E ratio is 18.01. In terms of profitability, CNTA's ROE is -0.60%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CNTA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CPRX's competition here
CNTA vs ACAD Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, CNTA is priced at $39.60, while ACAD trades at $22.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ACAD's P/E ratio is 10.00. In terms of profitability, CNTA's ROE is -0.60%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CNTA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ACAD's competition here
CNTA vs RYZB Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CNTA is priced at $39.60, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CNTA's ROE is -0.60%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CNTA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RYZB's competition here
CNTA vs CBAY Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CNTA is priced at $39.60, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CNTA's ROE is -0.60%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CNTA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CBAY's competition here
CNTA vs VKTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, CNTA is priced at $39.60, while VKTX trades at $31.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas VKTX's P/E ratio is -7.64. In terms of profitability, CNTA's ROE is -0.60%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, CNTA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check VKTX's competition here
CNTA vs TLX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, CNTA is priced at $39.60, while TLX trades at $10.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas TLX's P/E ratio is -543.00. In terms of profitability, CNTA's ROE is -0.60%, compared to TLX's ROE of -0.02%. Regarding short-term risk, CNTA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check TLX's competition here
CNTA vs EWTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, CNTA is priced at $39.60, while EWTX trades at $34.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas EWTX's P/E ratio is -20.49. In terms of profitability, CNTA's ROE is -0.60%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CNTA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check EWTX's competition here
CNTA vs DNTH Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, CNTA is priced at $39.60, while DNTH trades at $85.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas DNTH's P/E ratio is -20.17. In terms of profitability, CNTA's ROE is -0.60%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, CNTA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check DNTH's competition here
CNTA vs SWTX Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CNTA is priced at $39.60, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CNTA's ROE is -0.60%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, CNTA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check SWTX's competition here
CNTA vs ERAS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, CNTA is priced at $39.60, while ERAS trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ERAS's P/E ratio is -11.15. In terms of profitability, CNTA's ROE is -0.60%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CNTA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ERAS's competition here
CNTA vs NAMSW Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, NAMSW has a market cap of 3.1B. Regarding current trading prices, CNTA is priced at $39.60, while NAMSW trades at $27.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CNTA's ROE is -0.60%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, CNTA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check NAMSW's competition here
CNTA vs VCYT Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, VCYT has a market cap of 3.1B. Regarding current trading prices, CNTA is priced at $39.60, while VCYT trades at $38.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas VCYT's P/E ratio is 36.02. In terms of profitability, CNTA's ROE is -0.60%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, CNTA is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check VCYT's competition here
CNTA vs DNLI Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, CNTA is priced at $39.60, while DNLI trades at $19.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas DNLI's P/E ratio is -6.73. In terms of profitability, CNTA's ROE is -0.60%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, CNTA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check DNLI's competition here
CNTA vs BEAM Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, BEAM has a market cap of 3B. Regarding current trading prices, CNTA is priced at $39.60, while BEAM trades at $29.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas BEAM's P/E ratio is -60.27. In terms of profitability, CNTA's ROE is -0.60%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, CNTA is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BEAM's competition here
CNTA vs ALMS Comparison May 2026
CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CNTA stands at 6.1B. In comparison, ALMS has a market cap of 3B. Regarding current trading prices, CNTA is priced at $39.60, while ALMS trades at $24.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CNTA currently has a P/E ratio of -22.25, whereas ALMS's P/E ratio is -8.61. In terms of profitability, CNTA's ROE is -0.60%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, CNTA is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ALMS's competition here